PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer.
Saved in:
| Title: | PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. |
|---|---|
| Authors: | Cunningham ML; Department of Cell Biology and Regenerative Medicine, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Vasquez-Gonzalez J; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Barnada SM; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Tchotorlishvili S; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Jones L; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Maguire R; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Lewis G; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Rizwan K; Department of Medicine, Section Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA., Deng J; Department of Medicine, Section Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA., Koachar S; Department of Medicine, Section Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA., Patel D; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Shankle H; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Mulders T; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Ajmal N; Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA., Solomides C; Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA., Alnemri ES; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Alnemri TF; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA., Shafi AA; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Gomella LG; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kelly WK; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., McMahon SB; Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Schiewer MJ; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA. |
| Source: | Molecular oncology [Mol Oncol] 2026 Feb; Vol. 20 (2), pp. 369-388. Date of Electronic Publication: 2025 Sep 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70098 |
